Collegium Pharmaceutical, Inc. $COLL Shares Sold by Emerald Mutual Fund Advisers Trust

Emerald Mutual Fund Advisers Trust reduced its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 21.9% during the first quarter, Holdings Channel reports. The firm owned 306,074 shares of the specialty pharmaceutical company’s stock after selling 85,596 shares during the period. Emerald Mutual Fund Advisers Trust’s holdings in Collegium Pharmaceutical were worth $10,122,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Vident Advisory LLC boosted its holdings in Collegium Pharmaceutical by 1.9% during the third quarter. Vident Advisory LLC now owns 15,466 shares of the specialty pharmaceutical company’s stock worth $541,000 after buying an additional 281 shares in the last quarter. Quadrant Capital Group LLC increased its holdings in shares of Collegium Pharmaceutical by 4.2% in the fourth quarter. Quadrant Capital Group LLC now owns 6,996 shares of the specialty pharmaceutical company’s stock valued at $324,000 after buying an additional 282 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Collegium Pharmaceutical by 9.6% in the fourth quarter. GAMMA Investing LLC now owns 3,262 shares of the specialty pharmaceutical company’s stock valued at $151,000 after buying an additional 285 shares in the last quarter. Atom Investors LP lifted its position in shares of Collegium Pharmaceutical by 5.0% during the 4th quarter. Atom Investors LP now owns 6,124 shares of the specialty pharmaceutical company’s stock valued at $284,000 after acquiring an additional 294 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Collegium Pharmaceutical by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after acquiring an additional 318 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on COLL. Needham & Company LLC restated a “buy” rating and issued a $56.00 target price (up from $54.00) on shares of Collegium Pharmaceutical in a report on Thursday, March 19th. Zacks Research raised Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Monday, June 29th. Weiss Ratings reissued a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Monday, July 6th. HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Collegium Pharmaceutical in a report on Friday, March 20th. Finally, Truist Financial upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Collegium Pharmaceutical presently has a consensus rating of “Buy” and an average target price of $57.50.

Collegium Pharmaceutical Stock Down 1.2%

COLL stock opened at $34.82 on Tuesday. The company has a 50 day moving average of $34.71 and a two-hundred day moving average of $38.64. The company has a market cap of $1.13 billion, a price-to-earnings ratio of 17.07 and a beta of 0.73. Collegium Pharmaceutical, Inc. has a 12-month low of $29.19 and a 12-month high of $50.79. The company has a quick ratio of 1.62, a current ratio of 1.71 and a debt-to-equity ratio of 2.47.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.52 by $0.24. The firm had revenue of $193.52 million during the quarter, compared to analysts’ expectations of $184.47 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The business’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter last year, the firm earned $1.49 earnings per share. On average, equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current fiscal year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.